TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7696057
Drug: Continuous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous propofol and intermittent fentanyl (TIVA) with LMA, no neuromuscular blocker (Group 4)
Study: 7696057
Drug: Continuous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous propofol and intermittent fentanyl (TIVA) with LMA, neuromuscular blockers (Group 3)
Study: 2654200
Drug: Desipramine 75
Normalized name: desipramine 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 75 mg daily
Study: 31150315
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (3 cycles of fluorouracil, leucovorin, and oxaliplatin) before fluorouracil/oxaliplatin CRT (50.4 Gy)
Study: 31150315
Drug: Consolidation chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation chemotherapy after CRT
Study: 22151937
Drug: Samphire formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samphire formulations (0.1% serum, 0.05% cream, serum-cream association, 0.5% silicone oil)
Study: 20175799
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of ascorbic acid and 400 IU of alpha‐tocopherol (treatment group)
Study: 12515705
Drug: Standard Wedged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Wedged Treatment
Study: 14767299
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg finasteride daily for 4 years
Study: 24410738
Drug: SMS text-message
Normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS text-message intervention (structured programme of clinic appointment, medication pick-up reminders, medication adherence support, and hypertension-related education)
Study: 17515293
Drug: Demoksil 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demoksil 1 g tablet (test preparation)
Study: 17515293
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g tablet of the originator product (reference preparation)
Study: 17688076
Drug: Both test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both test and reference preparations
Study: 11441777
Drug: Access to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Access to evidence-based medicine
Study: 9142380
Drug: FLEP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLEP therapy (5‐fluorouracil 370 mg/m2, leucovorin 30 mg/person, cisplatinum 70 mg/m2, etoposide 70 mg/m2)
Study: 9142380
Drug: FLEP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLEP therapy followed by surgery
Study: 9142380
Drug: Curative surgery
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Curative surgery after FLEP therapy
Study: 7535443
Drug: GM‐/G‐CSF treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐/G‐CSF treatment prior to harvest
Study: 3495732
Drug: Trimethoprim-sulfamethoxazole given
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole given daily
Study: 29329484
Drug: Teriparatide 20 μg
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide 20 μg daily
Study: 29329484
Drug: Risedronate 35 mg
Normalized name: risedronate 35 MG
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate 35 mg weekly
Study: 15707470
Drug: Candesartan cilexetil
Normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Candesartan cilexetil (CC) 8 mg
Study: 15707470
Drug: Amlodipine (AML)
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine (AML) 5 mg
Study: 10639526
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide (NO) inhalation at 25 ppm with supplemental oxygen at 2 l/min via nasal cannula for 24 hours
Study: 10639526
Drug: Room air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air with supplemental oxygen at 2 l/min via nasal cannula for 24 hours (control)
Study: 1332988
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of metronidazole 25% gel
Study: 27187898
Drug: Stellate Ganglion
Normalized name: Mastocarpus stellatus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stellate Ganglion Block (SGB) - second treatment
Study: 18937864
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with house dust mite allergen
Study: 14740954
Drug: Candidate live-attenuated
Normalized name: varicella, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate live-attenuated dengue virus vaccine
Study: 11271080
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion starting with an initial dosage of 5 microg x kg x min, increased to a maximum of 10 microg x kg x min.
Study: 3007250
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg qid
Study: 30420291
Drug: Ω‐3 Long‐Chain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ω‐3 Long‐Chain PolyUnsaturated Fatty Acids (Ω‐3LCPUFA) 2.9 g/d
Study: 20433027
Drug: Dexamethasone sodium
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone sodium phosphate 8 mg (2 mL) intravenous
Study: 20433027
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution 2 mL intravenous (control)
Study: 16224674
Drug: Weak pulsing
Normalized name: weakleaf bur ragweed pollen extract
DrugBank: Ambrosia confertiflora pollen (DB10872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weak pulsing magnetic fields (daily exposure for 16 minutes over 6 weeks, frequencies of 10, 20, 30, and 200-300 Hz, flux densities from 3.4 to 13.6 microT)
Study: 16224674
Drug: Weak pulsing
Normalized name: weakleaf bur ragweed pollen extract
DrugBank: Ambrosia confertiflora pollen (DB10872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weak pulsing magnetic fields (after 4 weeks without therapy)
Study: 11908555
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (0.5 mg/kg)
Study: 11908555
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (1 mg/kg)
Study: 11908555
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (2 mg/kg)
Study: 11908555
Drug: ISIS 2302
Normalized name: ISIS-APOCIII-LRX
DrugBank: Olezarsen (DB18728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ISIS 2302 (all doses)
Study: 1522840
Drug: High-dose epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose epinephrine (7 mg)
Study: 30870416
Drug: Killed whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole cell-only oral cholera vaccine (WC-only OCV)
Study: 22762978
Drug: Parecoxib 20
Normalized name: parecoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib 20 mg (Group P(20))
Study: 22762978
Drug: Parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib 40 mg (Group P(40))
Study: 22762978
Drug: Lidocaine 40
Normalized name: lidocaine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 40 mg (Group L)
Study: 11965514
Drug: Olibra fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olibra fat (0, 2, 4, 6 g) in yoghurt
Study: 11965514
Drug: Control yoghurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control yoghurt (0 g Olibra)
Study: 11965514
Drug: Olibra fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olibra fat (0, 2, 4, 6 g)
Study: 10495984
Drug: Olanzapine 12.5-17.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 12.5-17.5 mg/day
Study: 7267697
Drug: diazepam with
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam with 120 ml water, preceded by 120 ml of a 50:50 vodka:water mixture
Study: 7267697
Drug: diazepam with
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam with 120 ml of the vodka mixture, preceded by 120 ml of water
Study: 7267697
Drug: diazepam with
Approvals — FDA: no, EMA: no, PMDA: no
Description: diazepam with 120 ml of water, preceded 30 min before with 120 ml of water (control)
Study: 28750582
Drug: MIN-101 32
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIN-101 32 mg/day
Study: 28750582
Drug: MIN-101 64
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIN-101 64 mg/day
Study: 28750582
Drug: MIN-101 32
Normalized name: OXT-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIN-101 32 mg/day and 64 mg/day
Study: 27264884
Drug: Whole body
Normalized name: MaxiVision Whole Body Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole body passive hyperthermia treatment (1h in 39.4±0.4°C water)
Study: 19707579
Drug: Bar graph
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bar graph showing proportion of people with symptoms on day three with and without treatment
Study: 17314584
Drug: Valdecoxib 40
Normalized name: valdecoxib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 40 mg q.d. (with a second dose on day 1)
Study: 15357650
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of lamivudine daily
Study: 15357650
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of lamivudine daily
Study: 7849144
Drug: Misoprostol 600
Normalized name: Misoprostol 600 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol 600 mg/day for 6 months
Study: 3381712
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg twice daily for 3 months)
Study: 3381712
Drug: Ketotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (1 mg twice daily for 5 months)
Study: 29982583
Drug: Hydrocortisone (HC)
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone (HC) 0.4 to 0.6 mg/kg body weight
Study: 22052306
Drug: Multiplexed 1,440
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiplexed 1,440 and 1,320 nm fractionated laser treatment
Study: 20225467
Drug: Conditioned for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conditioned for 7 days at 37 degrees C in 75% ethanol aqueous solution
Study: 20225467
Drug: Immersed in
Normalized name: OCTOCRYLENE 10 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL LOTION [Eucerin Face immersive Hydration]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immersed in fluoride gel (Elmex Gelée) at 37 degrees C for 1 hour
Study: 14607663
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg anisodamine
Study: 14607663
Drug: 0.75 mg
Normalized name: propinox 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 mg atropine
Study: 8384952
Drug: Local nervous
Normalized name: Syzygium nervosum flower bud extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local nervous blockade with bupivacaine (5 mg/ml) subcutaneously injected (15 ml)
Study: 3529000
Drug: labetalol 400
Normalized name: labetalol 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol 400 mg/day
Study: 31218636
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (systolic BP target: 110‐139 mmHg)
Study: 31218636
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment (systolic BP target: 140‐179 mmHg)
Study: 20347840
Drug: Massage therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage therapy (20-minute session between postoperative days 2 and 5)
Study: 15840102
Drug: Sodium lauryl
Normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lauryl sulphate (SLS) 1% cm(‐2) applied twice daily for 4 days
Study: 15840102
Drug: Sodium lauryl
Normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lauryl sulphate (SLS) 0.5% cm(‐2) applied twice daily for 4 days
Study: 15840102
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cold and SLS (SLS 1% or 0.5%) applied twice daily for 4 days
Study: 12416768
Drug: Chlorhexidine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine treatment (0.12% local irrigation and gel)
Study: 12416768
Drug: Mechanical cleansing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical cleansing and oral hygiene instructions (Control group)
Study: 9177613
Drug: Progestin-estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin-estrogen therapy (group I, 96 patients)
Study: 9177613
Drug: Antihypertensive drugs
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drugs (group II, 84 patients)
Study: 9177613
Drug: Progestin-estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin-estrogen therapy (for 23 unresponsive patients from group II)
Study: 1726458
Drug: University of
Normalized name: ALCOHOL 75 mL in 100 mL TOPICAL GEL [University of Michigan]
Approvals — FDA: no, EMA: no, PMDA: no
Description: University of Wisconsin solution preservation period (October 1987 to December 1988)
Study: 6275829
Drug: Simple sugars
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple sugars and starch added to a gelatine and cream cheese base (control)
Study: 23186035
Drug: GEn 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEn 1,200 mg/day
Study: 23186035
Drug: GEn 2,400
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEn 2,400 mg/day
Study: 23186035
Drug: GEn 3,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEn 3,600 mg/day
Study: 23186035
Drug: PGB 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGB 300 mg/day
Study: 21092934
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavior therapy (CBT) for IBS based on exposure and mindfulness exercises
Study: 17137560
Drug: d‐MPH‐ER 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH‐ER 20 mg
Study: 17137560
Drug: d‐MPH‐ER 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH‐ER 30 mg
Study: 17137560
Drug: d‐MPH‐ER 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH‐ER 40 mg
Study: 17137560
Drug: d‐MPH‐ER (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐MPH‐ER (all doses)
Study: 15102869
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dose of montelukast oral granules
Study: 15102869
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg film-coated tablet (FCT) in adults
Study: 12234056
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection (5 x 200 microl 5.8% NaCl)
Study: 12234056
Drug: Control leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control leg (no treatment)
Study: 9661616
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (1,000 micrograms/day, every 12 hours for 14 days)
Study: 2651567
Drug: Low/slow bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low/slow bromocriptine regimen (maximum 25 mg/day)
Study: 2651567
Drug: High/fast bromocriptine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High/fast bromocriptine regimen (maximum 100 mg/day)
Study: 175693
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with radiation therapy and 5-Fluorouracil
Study: 31375426
Drug: Soluble fibre
Normalized name: Soluble fibre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble fibre (inulin 12 g/day)
Study: 31375426
Drug: Soluble fibre
Normalized name: Soluble fibre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble fibre + probiotic (inulin 12 g/day + multi-strain probiotic >25 billion CFU)
Study: 24516951
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg oral lincomycin + high fiber (L + F)
Study: 22282954
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of clopidogrel 75 mg
Study: 22282954
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of clopidogrel 75 mg
Study: 20055193
Drug: Dexmedetomidine (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.7 microg x kg(‐1) x hr(‐1) after a bolus infusion at 6.0 microg x kg(‐1) x hr(‐1) for 10 min)
Study: 11694026
Drug: Nimesulide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide and Paracetamol
Study: 8187303
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (0.02‐0.05 IU/kg body weight subcutaneously at bedtime)
Study: 3129593
Drug: 1‐mg daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1‐mg daily intravenous injection of vitamin K
Study: 3129593
Drug: 10‐mg weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg weekly intramuscular injection of vitamin K
Study: 24583757
Drug: PUFA (eicosapentaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUFA (eicosapentaenoic acid 2160 mg and docosahexaenoic acid 1440 mg daily)
Study: 22985391
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2% lidocaine and then 10 mL of 0.75% ropivacaine (Group lr)
Study: 22985391
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of normal saline and then 10 mL of 0.75% ropivacaine (Group r)
Study: 22985391
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of 2% lidocaine and then 10 mL of 0.75% ropivacaine (Group LR)
Study: 22985391
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of normal saline and then 10 mL of 0.75% ropivacaine (Group R)
Study: 21330041
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg kg(‐1) adrenaline
Study: 17059437
Drug: cilostazol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilostazol (200 mg p.o.)
Study: 8985780
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection (ICI) of 20 micrograms/mL PGE1
Study: 8985780
Drug: Intracavernous injection
Normalized name: Bivalirudin 250 mg INTRACAVERNOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracavernous injection (ICI) of 25 micrograms/mL PGE1
Study: 8985780
Drug: Cocktail containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail containing 20 micrograms PGE1 plus 0.5 mg/mL phentolamine
Study: 8985780
Drug: Cocktail containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocktail containing 25 micrograms PGE1 plus 0.5 mg/mL phentolamine
Study: 1297297
Drug: rt-PA (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt-PA (100 mg/90 minutes; 10 mg bolus + 90 mg/90 minutes)
Study: 31146534
Drug: Rilpivirine Long
Normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rilpivirine Long Acting (RPV LA) 1,200 mg
Study: 29718715
Drug: Buprenorphine/naloxone (bup/nal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (bup/nal) treatment
Study: 29718715
Drug: Out-of-bup/nal-treatment group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Out-of-bup/nal-treatment group
Study: 11704083
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (two doses of 400 microg taken 2 h apart)
Study: 11704083
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (one dose of 800 microg)
Study: 9231214
Drug: Oral ofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ofloxacin, 15 mg/kg/d for 2 days
Study: 9231214
Drug: Oral ofloxacin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ofloxacin, 10 mg/kg/d for 3 days
Study: 26513847
Drug: Home-based oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based oral care training program
Study: 26513847
Drug: Routine oral
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine oral care education with swabs (Control)
Study: 23680334
Drug: Tapering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering of antihypertensive medications over 3 weeks (week 1: reduction by 25%-50%; week 2: 50%-75%; week 3: off)
Study: 23680334
Drug: Tapering of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapering of antihypertensive medications
Study: 12792318
Drug: Expectation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Expectation treatment (control)
Study: 1397914
Drug: Golytely (polyethylene
Normalized name: Golytely (polyethylene glycol 3350 236 GM / potassium chloride 2.97 GM / sodium bicarbonate 6.74 GM / sodium chloride 5.86 GM / sodium sulfate 22.74 GM) Powder for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golytely (polyethylene glycol electrolyte lavage solution) enema
Study: 27029851
Drug: 1000/200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000/200 mg of amoxicillin/clavulanate intravenously
Study: 27029851
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of amoxicillin by mouth